Sanofi reveals detailed timeframe for RSV candidate

Now that a new set of study data supports a possible treatment for RSV, Sanofi has laid out its plan for applying to regulatory authorities.

Photo: CHARLES PLATIAU/Reuters / X00217

Over the course of the first six months of 2022, Sanofi expects to submit the first regulatory application for marketing authorization for a possible treatment of respiratory syncytial virus (RSV) in infants.

In a press release, the company states that it has received results from a phase II/III trial of the drug nirsevimab, which supports the drug candidate.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs